Phase 3 Trial: Sotorasib and Panitumumab Combination Shows Increased Survival in Specific Patient Population

A recent Phase 3 clinical trial revealed that patients treated with a combination of sotorasib and panitumumab experienced increased survival times. The study investigated the efficacy of this drug combination in a specific patient population. Specifically, the Phase 3 trial assessed the impact of administering both sotorasib and panitumumab to patients. The results indicated that individuals who received this combined therapy lived longer compared to those who did not. Further analysis and review of the complete trial data are anticipated to provide a more comprehensive understanding of these findings.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

Author

Mark Chiang